Intrathecal and intracerebroventricular dopamine for Parkinson's disease.

Authors :: Abraham ME
Gold J
Dondapati A
Gendreau J
Mammis A
Herschman Y
Source :: Clinical neurology and neurosurgery [Clin Neurol Neurosurg] 2021 Jan; Vol. 200, pp. 106374. Date of Electronic Publication: 2020 Nov 23.
Publication Year :: 2021
Abstract: While CDD directly to the CSF can provide a constant delivery of the dopaminergic drug resulting in a more stable treatment effect without the limitations of traditional oral therapy without peripheral effects, it is still young and longitudinal data is lacking. These experimental therapies show promise and further investigation into their efficacy and safety could extend the frontiers for management of PD.<br /> (Copyright © 2020 Elsevier B.V. All rights reserved.)